Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 4800

Next Previous
Drug Profile

INO 4800

Alternative Names: COVID-19 DNA Vaccine - Inovio Pharmaceuticals; INO-4800

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals; University of Pennsylvania
  • Developer Advaccine (Suzhou) Biopharmaceuticals; Beijing Advaccine Biotechnology; Inovio Pharmaceuticals; World Health Organization
  • Class COVID-19 vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 30 Oct 2024 World Health Organization completes the phase III SOLIDARITY vaccine trial in COVID-2019 infections (Prevention) in Colombia, Kenya, Mali, Philippines, Sierra Leone, Switzerland (Intradermal) (ISRCTN15779782)
  • 27 Oct 2022 Discontinued - Phase-II for COVID-2019 infections (Prevention) in South Korea (Intradermal)
  • 27 Oct 2022 Discontinued - Phase-III for COVID-2019 infections (Prevention) in Thailand, India, Mexico, Colombia, Brazil, USA (Intradermal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top